Workflow
海利生物: 海利生物董事兼总经理集中竞价减持股份计划期满暨未减持股份结果公告

Summary of Key Points Core Viewpoint - The announcement details the results of the share reduction plan by the company's director and general manager, Han Benyi, indicating that he did not execute any share reductions during the specified period [1][2][3]. Shareholding Information - Before the reduction plan, Han Benyi held 3,000,000 shares, representing 0.4560% of the company's total share capital [1]. - Following the completion of a stock repurchase and cancellation plan, his shareholding decreased to 2,730,000 shares, which is 0.4164% of the adjusted total share capital of 655,662,200 shares [2]. Reduction Plan Implementation - The reduction plan was announced on February 20, 2025, with a proposed reduction of up to 750,000 shares, or 0.1140% of the total share capital, scheduled from March 14, 2025, to June 13, 2025 [1][2]. - As of the announcement date, Han Benyi did not reduce any shares, resulting in a total reduction of 0 shares and a remaining shareholding of 2,730,000 shares [2][3].